Industry reports
Editor highlights

Publication dates

All regions

Prostate Cancer Research Reports, April 2014

You might be interested in: cancer, medical equipment, therapeutics, more »


 

1-20 of about 5 900 reports for Prostate Cancer
Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • March 2014
  • by Global Data

... Key products in development include laquinimod, for the treatment of multiple sclerosis; tasquinimod for the treatment of prostate cancer; anyara for the treatment of renal cell cancer. Laquinimod ...

Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014

Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • March 2014
  • by Global Data

... Information and data relating to the clinical trials on hormone-sensitive prostate cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...

Analytical Tool - Prostate Cancer

Analytical Tool - Prostate Cancer

  • $ 4 650
  • Industry report
  • March 2014
  • by Bioseeker

... Analytical tool - prostate cancer "analytical tool - prostate cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer r ...

Prostate Cancer Drug Pathway Analyzer 2014

Prostate Cancer Drug Pathway Analyzer 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... Specifications3. Compare - you can overlay any pathways with each other and do a comparative analysisyou can interactively analyze any prostate cancer drug-pathway relationship by using up to four ...

Prostate Cancer Drug Pipeline Update 2014

Prostate Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

... To alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth.There are today 349 companies plus partners developing 414 drugs targeting prostate cancer ...

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014

  • $ 2 500
  • Industry report
  • March 2014
  • by Global Data

... Countries: proportion of hormone refractory (castration resistant, androgen-independent) prostate cancer to oncology clinical trials 17clinical trials by phase in g7 countries 18clinical trials in g7 ...

Prostate Cancer Partnering 2009-2014

Prostate Cancer Partnering 2009-2014

  • $ 995
  • Industry report
  • March 2014
  • by Currentpartnering

... Report contains over 160 links to online copies of actual prostate cancer deals and contract documents as submitted to the securities exchange commission by companies and their partners, where available ...

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014

  • $ 2 000
  • Industry report
  • February 2014
  • by Global Markets Direct

... Castration resistant, androgen-independent) prostate cancer pipeline on the basis of target, moa, route of administration and molecule type- latest news and deals relating related to pipeline products ...

Algeta ASA (Symbol:ALGETA) SWOT Analysis, Strategy, Revenues and Profits

Algeta ASA (Symbol:ALGETA) SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • February 2014
  • by Global Data

... Such as hormone-refractory prostate cancer, lung, breast and kidney cancers. Its lead product cand, radium-223 was approved in the us under the brand name xofigo. It was developed under an agreement with bayer ...

Cancer Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cancer Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • February 2014
  • by Global Data

... Immunology and cancer immunology research. It conducts clinical trials for several cancer types such as breast cancer, colorectal cancer, lung cancer, melanoma and prostate cancer. Cri's cancer immunotherapy ...


» Read our Company Profiles

2 Companies for Prostate Cancer

Management Strategies

United States

Johnson and Johnson

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.